Faculty, Staff and Student Publications
Publication Date
1-7-2023
Journal
JCO Precision Oncology
DOI
10.1200/PO.22.00540
PMID
36716413
PMCID
PMC9928880
PubMedCentral® Posted Date
January 2023
PubMedCentral® Full Text Version
Post-print
Abstract
PURPOSE: Local consolidative therapy (LCT) for patients with synchronous oligometastatic non-small-cell lung cancer is an evolving treatment strategy, but outcomes following LCT stratified by genetic mutations have not been reported. We sought to identify genomic associations with overall survival (OS) and progression-free survival (PFS) for these patients.
METHODS: We identified all patients presenting between 2000 and 2017 with stage IV non-small-cell lung cancer and ≤ 3 synchronous metastatic sites. Patients were grouped according to mutational statuses. Primary outcomes included OS and PFS following initial diagnosis.
RESULTS: Of 194 included patients, 121 received comprehensive LCT to all sites of disease with either surgery or radiation.
CONCLUSION: When compared with wild-type patients, those with
Keywords
Humans, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Benchmarking, Proto-Oncogene Proteins p21(ras), Mutation, ErbB Receptors
Published Open-Access
yes
Recommended Citation
De, Brian; Farooqi, Ahsan S; Mitchell, Kyle G; et al., "Benchmarking Outcomes for Molecularly Characterized Synchronous Oligo metastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival" (2023). Faculty, Staff and Student Publications. 1422.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/1422
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Oncology Commons